<DOC>
	<DOCNO>NCT02521389</DOCNO>
	<brief_summary>This single center first human ( FIH ) study comprise 2 part ; Part 1 consist 3 sequential dose group ( Groups A , B C ) Part 2 consist 1 dose group ( Group A ) . There option include 2 additional dose group Part 1 ( Groups D E ) ass alternative dose level formulation , require . In study part , subject receive single dose investigational medicinal product PWT-143 2 study period ( total 2 single dos ) .</brief_summary>
	<brief_title>Assessment Safety , Tolerability , Pharmacokinetics Pharmacodynamics Various Formulations Doses PWT-143</brief_title>
	<detailed_description>This first-in-human study comprise 2 part . In part , subject receive single dose investigational medicinal product ( IMP ) 2 study period ( total 2 single dos ) . Part 1 ( Single Ascending Dose ) This open-label , single dose design . It plan enroll 3 sequential group ( Groups A , B C ) , comprise 3 , 6 6 subject , respectively , 2 optional additional group ( Groups D E ) , comprise 6 subject , assess alternative dose level formulation ( describe ) , require . The start dose , dose increment dose range base available pre-clinical data . Current plan dose level : 10 , 30 , 60 , 90 150 mg ( dose level 1 , 2 , 3 , 4 5 , respectively ) ; however , dose 10 mg select base review emerge data study . It plan use Formulation 1 dose administration Part 1 ( Group A ) , select 3 test formulation . However , base exposure see emerge data , alternative formulation may select dose comparison escalation . Part 2 ( Food Effect Assessment ) This open-label , randomise , single dose , 2-way crossover design ass select formulation PWT-143 fed fast state . Subjects administer single dose investigational medicinal product feed fasted state across 2 study period accord randomisation schedule . There minimum washout period PWT-143 7 day dose administration Periods 1 2 . It plan 1 group comprise 8 subject participate Part 2 . Subjects consider evaluable receive treatment ( ie , fed fast ) complete safety assessment PK sample 24 h post-dose .</detailed_description>
	<criteria>1 . Healthy male 2 . Age 18 65 year age 3 . Body mass index 18.0 32.0 kg/m2 , outside range , consider clinically significant investigator 4 . Part 2 : Must able consume food item standard high fat breakfast and/or condition surgery ( eg , cholecystectomy ) could affect ability eat high fat breakfast 5 . Must willing able communicate participate whole study 6 . Must willing provide voluntary write informed consent performance studyrelated procedure part normal medical care 7 . Must agree use adequate method contraception 1 . Healthy male 2 . Age 18 65 year age 3 . Body mass index 18.0 32.0 kg/m2 , outside range , consider clinically significant investigator 4 . Part 2 : Must able consume food item standard high fat breakfast and/or condition surgery ( eg , cholecystectomy ) could affect ability eat high fat breakfast 5 . Must willing able communicate participate whole study 6 . Must willing provide voluntary write informed consent performance studyrelated procedure part normal medical care 7 . Must agree use adequate method contraception</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>